Precisely! So who benefits based on the Phase 3 data? Methylated, mesenchymal and rGBM patients who are some of the worst prognosis patients historically and make up to or over 50% of the overall patient population. Then there is the Specials data which likely points to increased benefit under certain similar circumstances as well in other cancer types especially those with the most targets to go after ( heterogenous). Limits imposed on a treatment that covers cancer as the indication opens up quite a few patients for consideration even if excluding non methylated or non mesenchymal signature patients because that signature moves into to ~85% range at recurrence in GBM. Just rGBM patients alone at a 50% rate would pretty much take care of artisan capacity and Dr. Ashkan and all of his protégés would make sure patients in their care who qualify get this treatment. Just sayin; ). Best wishes.
Market Data 
Markets 
AI
